Medical/Pharmaceuticals
HistoSonics Announces Agreement with GE Healthcare
HistoSonics Breakthrough Liver Therapy System to Utilize GE's LOGIQ™ E10 for Real-Time Imaging Guidance and Treatment Verification MINNEAPOLIS, May 23, 2022 /PRNewswire/ -- HistoSonics Inc., developer of a completely non-invasive platform using the science of histotripsy, today announced an agre...
2022-05-23 21:00
3768
New Horizon Health Partners with Prenetics in Hong Kong to Launch ColoClear, a Non-Invasive Stool DNA Test to Detect Colon Cancer
HANGZHOU, China and HONG KONG, May 23, 2022 /PRNewswire/ -- New Horizon Health (6606.HK) and Prenetics Group Limited (Nasdaq: PRE, "Prenetics") has announced a strategic partnership to launch ColoClear by Circle (ColoClear), the "First Colorectal Cancer Screening Test approved inChina", in Hong K...
2022-05-23 20:46
5476
KAZIA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES HOSTED BY HC WAINWRIGHT AND LD MICRO
SYDNEY, May 23, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, DrJames Garner, will be presenting at two upcoming investor conferences. Dr Garner will present on behalf of Kazia at the HC ...
2022-05-23 20:30
4074
Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New Zealand
The latest geographic growth increases Medison's global footprint across 25
countries in four continents, further strengthening its commercial offering
PETACH TIKVAH, Israel, May 23, 2022 /PRNewswire/ -- Medison Pharma
2022-05-23 20:28
4587
VISEN Pharmaceuticals Announces Top-line Results of Phase 3 Trial of Once-Weekly Lonapegsomatropin, Demonstrating Superior Efficacy, Comparable Safety and Tolerability to Daily Growth Hormone
SHANGHAI, May 23, 2022 /PRNewswire/ -- VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, today announced positive top-line results from its pivotal phase 3 trial, a randomized, open-label, active-controlled trial that compared lonapegsomatropin (TransCo...
2022-05-23 15:57
1796
Antengene Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas
SHANGHAI and HONG KONG, May 23, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer...
2022-05-23 10:10
4068
Hanmi Fine Chemical Launches 'high-tech CDMO' Business
CDMO business initiated such as mRNA vaccine raw materials·peptides 10 billion KRW invested in Hanmi Fine Chemical facility expansion SEOUL, South Korea, May 22, 2022 /PRNewswire/ -- Hanmi Fine Chemical (hereinafter Hanmi FC) a subsidiary of Hanmi Pharmaceutical Group specializing in APIs(Active...
2022-05-23 08:32
3379
WHO Goodwill Ambassador for Leprosy Elimination Recognized with WHO Director-General's Award for Global Health at 75th World Health Assembly
Ambassador will call on countries to strengthen efforts against leprosy in meetings with delegations attending WHA TOKYO, May 22, 2022 /PRNewswire/ -- WHO Goodwill Ambassador for Leprosy Elimination Yohei Sasakawa arrives inGeneva, Switzerland on May 23 for the 75th World Health Assembly, where ...
2022-05-23 00:00
3019
Tulip Partners with Stanley Black & Decker on Global Operations Platform
* Platform to provide digital manufacturing solutions for Stanley Black & Decker operations * Jane Arnold, Vice President of Manufacturing Technology at Stanley Black & Decker, to join Tulip's Board of Directors BOSTON, May 21, 2022 /PRNewswire/ -- Tulip Interfaces ("Tulip") announced today t...
2022-05-21 03:53
11217
Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
-- European Commission Decision Anticipated within Approximately 60 Days -- NEWTON, Mass. and FLORENCE, Italy, May 21, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini")...
2022-05-21 01:19
11335
Meihua International Medical Technologies Co., Ltd. Receives Notification of Deficiency from Nasdaq Related to Delayed Annual Report on Form 20-F
YANGZHOU, China, May 20, 2022 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries inChina, today announced that on May 18,...
2022-05-20 22:57
7988
Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias
EPLive 2022 is a two-day conference that draws the world's top cardiac electrophysiology experts AUSTIN, Texas, May 20, 2022 /PRNewswire/ -- On June 2 and 3, 2022, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its sixth international symposium on complex a...
2022-05-20 20:08
5516
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
* Emerald study met both its primary end points of Progression-free survival (PFS) in overall population and in ESR1 mutated patients * PFS rate at 12 months with elacestrant was 22.32% vs. 9.42% with SOC in the overall population, and 26.76% vs. 8.19% in theESR1 mutation population * Data d...
2022-05-20 16:17
4913
Lipidor updates on Phase III study of AKP02 in treatment of psoriasis - half of patients now recruited
STOCKHOLM, May 20, 2022 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that half of the patients have now been enrolled in the Phase III study of AKP02 skin spray for mild to moderate psoriasis, with the last patient expected to begin treatment inJune 2022. T...
2022-05-20 14:56
3349
Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit
GAITHERSBURG, Md. and SUZHOU, China, May 20, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Company's Executive Director and Chief Medical O...
2022-05-20 12:31
4767
Clinical trial results of Belief BioMed's hemophilia B gene therapy drug candidate BBM-H901 published in The Lancet Haematology
SHANGHAI, May 20, 2022 /PRNewswire/ -- The early phase clinical trial results of BBM-H901, the first intravenously injectable hemophilia B gene therapy product developed and tested inAsia, are published in The Lancet Haematology, a top international journal in hematology. https://www.thelancet....
2022-05-20 10:43
9544
CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing
TIANJIN, China, May 19, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that the World Health Organization ("WHO") has granted Emergency Use Listing ("EUL") for Convidecia™, CanSinoBIO's Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5...
2022-05-19 23:28
5018
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, May 19, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of can...
2022-05-19 22:39
3298
All Border Ports in Guangxi Commenced Normal Operations
NANNING, China, May 19, 2022 /PRNewswire/ -- Statistics from the Department of Commerce of Guangxi Zhuang Autonomous Region show that during the May Day holiday in 2022, a total of 3,344 vehicles entered and exited throughGuangxi border highway ports, including 1,601 and 1,743 vehicles leaving an...
2022-05-19 21:39
3182
Lunit AI Biomarker PD-L1 Demonstrates Clinical Efficacy as Diagnostic Aid in Cancer Treatment-Published in the European Journal of Cancer
* Study findings show that Lunit's AI-powered PD-L1 TPS analyzer minimizes interpretation discrepancy among pathologists * AI-assisted PD-L1 TPS reading using Lunit SCOPE PD-L1 leads to better prediction of therapeutic outcomes in non-small cell lung cancer patients * In April 2022, Lunit SC...
2022-05-19 21:00
1957
Week's Top Stories
Most Reposted
OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1141 media titles]
2026-11-05 06:52Royal Bank of Canada announces agreement to acquire Yarra Capital Management
[Picked up by 1141 media titles]
2026-11-09 21:00Algolia Powers Orange with AI Agents for Billing Support: NYSE Content Update
[Picked up by 1121 media titles]
2026-11-06 22:06
Cision Report Reveals the Consumer Trends Hidden Between Search, Social, and AI
[Picked up by 1105 media titles]
2026-11-09 23:00
Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1083 media titles]
2026-11-03 22:00Most Read
Home Companion Robot Mobo to Debut Globally and Open Pre-orders as AiMOGA Showcases Its Robot Family at the 2026 OMODA & JAECOO International User Summit
2026-11-07 13:49
25933
ZD Energy Unveils Overseas Smart Energy Solutions in Thailand, Leveraging Local Manufacturing and Scenario-Based Capabilities to Support the Country's Energy Transition
2026-11-06 22:12
14837
SILVERSEA MARKS HISTORIC OPENING OF THE CORMORANT AT 55 SOUTH, THE SOUTHERNMOST HOTEL ON EARTH, OFFERING A NEW GATEWAY TO ANTARCTICA
2026-11-07 01:05
14355
OceanaGold Reports Third Quarter 2026 Results
2026-11-05 06:52
14177